LXRX Q1 2025 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+11.7% YoY

Gross Profit

$1M97.6% margin

Operating Income

-$26M-2034.8% margin

Net Income

-$25M-2004.4% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-95.2%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$44M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$298M

Total Liabilities

$175M

Stockholders' Equity

$123M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	+11.7%
Gross Profit	$1M	$955,000	+29.0%
Operating Income	-$26M	-$45M	+43.4%
Net Income	-$25M	-$48M	+47.7%

Revenue Segments

License

$45100%